

## 2018 Information

Date of announcement	Date of announcement	Statement
2018/1/24	16:38:10	<p>Invited to brief recent operating results</p> <p>1.Date of the investor conference:2018/01/26</p> <p>2.Time of the investor conference:14:30</p> <p>3.Location of the investor conference:22F., No.2, Sec. 1, Chongqing S. Rd., Taipei City</p> <p>4.Brief information disclosed in the investor conference: Brief recent operating results</p> <p>5.The presentation of the investor conference release:  <a href="http://webpro2.twse.com.tw/WebPortal/">http://webpro2.twse.com.tw/WebPortal/</a></p> <p>6.Will the presentation be released in the Company's website:  <a href="http://www.sci-pharmtech.com.tw">http://www.sci-pharmtech.com.tw</a></p> <p>7.Any other matters that need to be specified:NA</p>
2018/3/9	15:30:20	<p>The Board proposed earnings distribution.</p> <p>1.Date of the board of directors resolution :2018/03/09</p> <p>2.Appropriations of earnings in cash dividends to shareholders (NT\$ per share):2.15</p> <p>3.Cash distributed from legal reserve and capital surplus to shareholders (NT\$ per share):0</p> <p>4.Total amount of cash distributed to shareholders (NT\$):170,893,417</p> <p>5.Appropriations of earnings in stock dividends to shareholders (NT\$ per share):0</p> <p>6.Stock distributed from legal reserve and capital surplus to shareholders (NT\$ per share):0</p> <p>7.Total amount of stock distributed to shareholders (shares):0</p> <p>8.Any other matters that need to be specified:NA</p>
2018/3/9	15:30:35	<p>Donation to related party.</p> <p>1.Date of occurrence of the event:2018/03/09</p> <p>2.The reason for the donation:Support Criminal study</p> <p>3.The total amount of the donation:NTD300,000</p> <p>4.Counterparty to the donation:Criminal Investigation Foundation of R.O.C.</p> <p>5.Relationship to the Company:Related Party</p> <p>6.Name and resume of the independent director that expressed objection or reservation:NA</p> <p>7.Contents of the objection or reservation:NA</p> <p>8.Any other matters that need to be specified:NA</p>

2018/3/9	15:30:50	<p>Board of Directors approved the compensation for employees and directors of 2017</p> <ol style="list-style-type: none"> <li>1.Date of occurrence of the event:2018/03/09</li> <li>2.Company name:SCI Pharmtech, Inc.</li> <li>3.Relationship to the Company (please enter "head office" or "subsidiaries"):head office</li> <li>4.Reciprocal shareholding ratios:NA</li> <li>5.Cause of occurrence:NA</li> <li>6.Countermeasures:NA</li> <li>7.Any other matters that need to be specified: <ol style="list-style-type: none"> <li>(1)Employees' compensation was NT\$22,989,000</li> <li>(2)Directors' compensation was NT\$3,134,863</li> <li>(3)The above compensations will be distributed in cash.</li> <li>(4)The total amount approved is not different from the expense recognized in 2017 financial statements.</li> </ol> </li> </ol>
2018/3/9	15:37:39	<p>Convention of 2018 general shareholders' meeting.</p> <ol style="list-style-type: none"> <li>1.Date of the board of directors resolution:2018/03/09</li> <li>2.Date for convening the shareholders' meeting:2018/06/26</li> <li>3.Location for convening the shareholders' meeting: No.55, Changrong Rd., Luzhu Dist., Taoyuan City, Taiwan (Freedom design hotel)</li> <li>4.Cause or subjects for convening the meeting (1)Report Items: <ol style="list-style-type: none"> <li>(1)Report on the compensation for employees and directors of 2017</li> <li>(2)Report on operating results of 2017</li> <li>(3)Report by Audit Committee on auditing of 2017 financial statements</li> <li>(4)Report on donation to related parties</li> <li>(5)Amendment to Rules of Procedure for Board of Directors Meeting</li> </ol> </li> <li>5.Cause or subjects for convening the meeting (2)Matters for Ratification: <ol style="list-style-type: none"> <li>(1)Recognition of 2017 operation report and financial statements</li> <li>(2)Distribution of retained earnings</li> </ol> </li> <li>6.Cause or subjects for convening the meeting (3)Matters for Discussion:N/A</li> <li>7.Cause or subjects for convening the meeting (4)Elections: N/A</li> <li>8.Cause or subjects for convening the meeting (5)Other Proposals: N/A</li> <li>9.Cause or subjects for convening the meeting (6)Extemporary Motions: N/A</li> <li>10.Book closure starting date:2018/04/28</li> <li>11.Book closure ending date:2018/06/26</li> <li>12.Any other matters that need to be specified: N/A</li> </ol>
2018/4/24	18:24:42	<p>Invited to brief recent operating results</p> <ol style="list-style-type: none"> <li>1.Date of the investor conference:2018/04/25</li> <li>2.Time of the investor conference:14:45</li> <li>3.Location of the investor conference:12F., No.700, Mingshui Rd., Taipei City</li> </ol>

		<p>4. Brief information disclosed in the investor conference: Brief recent operating results</p> <p>5. The presentation of the investor conference release:  <a href="http://webpro2.twse.com.tw/WebPortal/">http://webpro2.twse.com.tw/WebPortal/</a></p> <p>6. Will the presentation be released in the Company's website:  <a href="http://www.sci-pharmtech.com.tw">http://www.sci-pharmtech.com.tw</a></p> <p>7. Any other matters that need to be specified: NA</p>
2018/6/26	14:37:09	<p>Notice of the resolutions of 2018 general shareholders' meeting.</p> <p>1. Date of the shareholders' meeting: 2018/06/26</p> <p>2. Important resolutions (1) profit distribution/deficit compensation:  Approved the distribution of retained earnings.  47,427,571 shares represented by shareholders present in person or by proxy.  (including 29,027,777 shares casted electronically)  approval votes : 45,873,223 votes - 96.72% of the total represented at the time of voting.  disapproval votes : 3,794 votes - 0.00% of the total represented at the time of voting.  invalid votes: 0 votes - 0% of the total represented at the time of voting.  abstention votes/no votes : 1,550,554 votes - 3.26% of the total represented at the time of voting.</p> <p>3. Important resolutions (2) amendments of the corporate charter: NA</p> <p>4. Important resolutions (3) business report and financial statements:  Approved the operation report and financial statement of 2017.  47,427,571 shares represented by shareholders present in person or by proxy.  (including 29,027,777 shares casted electronically)  approval votes : 45,873,222 votes - 96.72% of the total represented at the time of voting.  disapproval votes : 3,791 votes - 0.00% of the total represented at the time of voting.  invalid votes: 0 votes - 0% of the total represented at the time of voting.  abstention votes/no votes : 1,550,558 votes - 3.26% of the total represented at the time of voting.</p> <p>5. Important resolutions (4) elections of board of directors and supervisors: NA</p> <p>6. Important resolutions (5) other proposals: NA</p> <p>7. Any other matters that need to be specified: NA</p>
2018/6/26	15:26:34	<p>Notice of the record date for common share dividend.</p> <p>1. Date of the resolution by the board of directors or shareholders' meeting or decision by the Company: 2018/06/26</p> <p>2. Type of ex-rights or ex-dividend (please enter: "Ex-rights", "Ex-dividend", or "Ex-rights and dividend"): Ex-dividend</p> <p>3. Type and monetary amount of dividend distribution: Cash dividends of NT\$170,893,417</p>

		<p>4.Ex-rights (ex-dividend) trading date:2018/07/31</p> <p>5.Last date before book closure:2018/08/01</p> <p>6.Book closure starting date:2018/08/02</p> <p>7.Book closure ending date:2018/08/06</p> <p>8.Ex-rights (ex-dividend) record date:2018/08/06</p> <p>9.Any other matters that need to be specified: The payment date of the cash distribution is August 17, 2018.</p>
2018/6/26	15:26:49	<p>Donation to related party.</p> <p>1.Date of occurrence of the event:2018/06/26</p> <p>2.The reason for the donation:Promote domestic sports culture</p> <p>3.The total amount of the donation:NT\$1,500,000</p> <p>4.Counterparty to the donation:Foundation for Taiwan Masters Golf Tournament</p> <p>5.Relationship to the Company:Related Party</p> <p>6.Name and resume of the independent director that expressed objection or reservation:NA</p> <p>7.Contents of the objection or reservation:NA</p> <p>8.Any other matters that need to be specified:NA</p>
2018/8/29	13:54:39	<p>Invited to brief recent operating results</p> <p>1.Date of the investor conference:2018/08/30</p> <p>2.Time of the investor conference:14:30</p> <p>3.Location of the investor conference:20F., No.2, Sec. 1, Chongqing S. Rd., Taipei City</p> <p>4.Brief information disclosed in the investor conference: Brief recent operating results</p> <p>5.The presentation of the investor conference release: <a href="http://webpro2.twse.com.tw/WebPortal/">http://webpro2.twse.com.tw/WebPortal/</a></p> <p>6.Will the presentation be released in the Company's website: <a href="http://www.sci-pharmtech.com.tw">http://www.sci-pharmtech.com.tw</a></p> <p>7.Any other matters that need to be specified:NA</p>
2018/10/31	17:33:17	<p>Invited to brief recent operating results</p> <p>1.Date of the investor conference:2018/10/11</p> <p>2.Time of the investor conference:14:30</p> <p>3.Location of the investor conference:3F., No.236 Sec 4, Hsin-I Rd., Taipei City</p> <p>4.Brief information disclosed in the investor conference: Brief recent operating results</p> <p>5.The presentation of the investor conference release: <a href="http://webpro2.twse.com.tw/WebPortal/">http://webpro2.twse.com.tw/WebPortal/</a></p>

		<p>6. Will the presentation be released in the Company's website:  <a href="http://www.sci-pharmtech.com.tw">http://www.sci-pharmtech.com.tw</a></p> <p>7. Any other matters that need to be specified: NA</p>
<p>2018/11/9</p>	<p>16:49:34</p>	<p>Declare that the Company is going to acquire privately placed securities</p> <p>1. Name and nature of the subject matter (if preferred shares, the terms and conditions of issuance shall also be indicated, e.g. dividend yield):  Privately placed securities of Energenesis Biomedical Co., Ltd.</p> <p>2. Date of occurrence of the event: 2018/11/09</p> <p>3. Volume, unit price, and total monetary amount of the transaction:  Total amount: no more than NTD30 million  Unit price: 80% average closing price of the 30 days right before Energenesis' board meeting on Nov. 21.  Volume: uncertain</p> <p>4. Counterpart to the trade and its relationship to the Company (if the trading counterpart is a natural person and furthermore is not an actual related party of the Company, the name of the trading counterpart is not required to be disclosed): Energenesis Biomedical Co., Ltd.</p> <p>5. Where the counterpart to the trade is an actual related party, a public announcement shall also be made of the reason for choosing the related party as trading counterpart and the identity of the previous owner (including its relationship with the company and the trading counterpart), price of transfer, and date of acquisition: None</p> <p>6. Where a person who owned the property within the past five years has been an actual related person of the company, a public announcement shall also include the dates and prices of acquisition and disposal by the related person and the person's relationship to the company at those times: None</p> <p>7. Matters related to the creditor's rights currently being disposed of (including types of collateral of the disposed creditor's rights; if the creditor's rights are creditor's rights toward a related person, the name of the related person and the book amount of the creditor's rights toward such related person currently being disposed of must also be announced): None</p> <p>8. Anticipated profit or loss from the disposal (not applicable in cases of acquisition of securities) (where originally deferred, the status or recognition shall be stated and explained): None</p> <p>9. Terms of delivery or payment (including payment period and monetary amount), restrictive covenants in the contract, and other important stipulations: Payment term: 2018/11/21-2018/11/30</p> <p>10. The manner in which the current transaction was decided, the reference basis for the decision on price, and the decision-making department:  The transaction was decided by both audit committee meeting and board meeting and the price was based on 80% average closing price of the</p>

		<p>30 days right before Energenesis' board meeting on Nov. 21.</p> <p>11.Net worth per share of company underlying securities acquired or disposed of: TWD9.88</p> <p>12.The discrepancy between the reference price of private placement and the transaction amount per share is 20 percent or more of the transaction amount: N/A</p> <p>13.Current cumulative volume, amount, and shareholding percentage of holdings of the security being traded (including the current trade) and status of any restriction of rights (e.g.pledges): 0</p> <p>14.Current ratio of private placement of securities (including the current trade) to the total assets and shareholder's equity as shown in the most recent financial statement and the operating capital as shown in the most recent financial statement:</p> <p>To total assets:0.91%</p> <p>To shareholder's equity:1.01%</p> <p>To operating capital: 3.12%</p> <p>15.Broker and broker's fee: None</p> <p>16.Concrete purpose or use of the acquisition or disposition: To stabilize the foundation of business cooperation and form strategic alliance.</p> <p>17.Do the directors have any objection to the present transaction? : No</p> <p>18.The trading counterparty is a related party: No</p> <p>19.Approval date by board of directors:2018/11/09</p> <p>20.Recognition date by supervisors or submission date by audit committee: 2018/11/09</p> <p>21.Has the CPA issued an opinion on the unreasonableness of the price of the current transaction? : None</p> <p>22.Any other matters that need to be specified: Energenesis' board meeting will be held on Nov. 21 to decide on the issuance price.</p>
--	--	---